Long-acting inhaled β2-agonist therapy in asthma

[1]  P. Barnes,et al.  Comparison of the effects of salmeterol and formoterol in patients with severe asthma. , 2002, Chest.

[2]  D. Postma,et al.  Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial , 2001, The Lancet.

[3]  E. Kerwin,et al.  Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. , 2000, The Journal of allergy and clinical immunology.

[4]  B. Lipworth,et al.  Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. , 2000, Chest.

[5]  A. Tattersfield,et al.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects , 2000, Thorax.

[6]  Pearce,et al.  Association of β2‐adrenergic receptor polymorphisms with severe asthma , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  J. Lötvall,et al.  Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics , 2000, European Journal of Clinical Pharmacology.

[8]  M. Lindsay,et al.  Delayed eosinophil apoptosis in asthma. , 2000, The Journal of allergy and clinical immunology.

[9]  A. von Berg,et al.  Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. , 2000, Respiratory medicine.

[10]  M. Grunstein,et al.  Autocrine cytokine signaling mediates effects of rhinovirus on airway responsiveness. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[11]  M. Kavuru,et al.  Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. , 2000, The Journal of allergy and clinical immunology.

[12]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[13]  C. Schramm,et al.  Dexamethasone potentiates high-affinity β-agonist binding and Gsα protein expression in airway smooth muscle , 2000 .

[14]  R. Hancox,et al.  Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. , 2000, American journal of respiratory and critical care medicine.

[15]  A. Knox,et al.  Synergistic Inhibition by β2-Agonists and Corticosteroids on Tumor Necrosis Factor- α –Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells , 2000 .

[16]  H. Bisgaard.  Long‐acting β2‐agonists in management of childhood asthma: A critical review of the literature , 2000 .

[17]  R. Pauwels,et al.  A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. , 2000, American journal of respiratory and critical care medicine.

[18]  K. Chung,et al.  No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. , 2000, American journal of respiratory and critical care medicine.

[19]  W. Lumry,et al.  Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma , 2000 .

[20]  M. Noppen,et al.  Bronchodilating Effect of Formoterol but Not of Salmeterol in Two Asthmatic Patients , 2000, Respiration.

[21]  M. Laviolette,et al.  Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. , 1999, American journal of respiratory and critical care medicine.

[22]  R. Dahl,et al.  Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. , 1999, Respiratory medicine.

[23]  M. Aubier,et al.  Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. , 1999, Respiratory medicine.

[24]  F. Thien,et al.  An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. , 1999, American journal of respiratory and critical care medicine.

[25]  I. Hall,et al.  Effects of a range of β2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells , 1999 .

[26]  Hall.  β2‐adrenoceptor polymorphisms and asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  E. R. Mcfadden,et al.  Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. , 1999, The American journal of medicine.

[28]  S. Durham.  Long acting inhaled beta2-agonists: anti-inflammatory effects not evident during treatment of day to day asthma. , 1999, The European respiratory journal.

[29]  D. Postma,et al.  Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. , 1999, American journal of respiratory and critical care medicine.

[30]  P. Howarth,et al.  The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. , 1999, The European respiratory journal.

[31]  B. Lipworth,et al.  Comparative trough effects of formoterol and salmeterol on lymphocyte β2-adrenoceptor – regulation and bronchodilatation , 1999, European Journal of Clinical Pharmacology.

[32]  J. Lötvall,et al.  Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. , 1999, American journal of respiratory and critical care medicine.

[33]  P. Paggiaro,et al.  Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects , 1999, Thorax.

[34]  W. Busse,et al.  Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. , 1999, The Journal of allergy and clinical immunology.

[35]  P. Barnes,et al.  Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. , 1999, American journal of respiratory and critical care medicine.

[36]  R. Aalbers,et al.  Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. , 1999, The European respiratory journal.

[37]  B. Lipworth,et al.  In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol. , 1999, The Journal of allergy and clinical immunology.

[38]  C. Burke,et al.  A comparison of the efficacy of long-acting β2-agonists: eformoterol via Turbohaler® and salmeterol via pressurized metered dose inhaler or Accuhaler®, in mild to moderate asthmatics , 1999 .

[39]  D. Postma,et al.  Budesonide and formoterol exert an additive effect on the inhibition of ICAM-1 and VCAM-1 upregulation and GM-CSF production of human lung fibroblasts , 1999 .

[40]  M. Fairbarn,et al.  Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. , 1999, The Journal of allergy and clinical immunology.

[41]  B. Lipworth,et al.  A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. , 1999, Chest.

[42]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[43]  O. Eickelberg,et al.  Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells* , 1999, The Journal of Biological Chemistry.

[44]  M. Andersson,et al.  E V ects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects , 1998 .

[45]  Malcolm W Johnson.  The β -Adrenoceptor , 1998 .

[46]  A. Knox,et al.  Role of cyclo‐oxygenase‐2 induction in interleukin‐1β induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline , 1998, British journal of pharmacology.

[47]  K. Chung,et al.  A Comparison of Low-Dose Inhaled Budesonide Plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma , 1998 .

[48]  J. Heyder,et al.  Prostanoids mediate IL-1β-induced β-adrenergic hyporesponsiveness in human airway smooth muscle cells. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[49]  I. Hall,et al.  Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. , 1998, The European respiratory journal.

[50]  O. Selroos,et al.  Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients. , 1998, The European respiratory journal.

[51]  G. Town,et al.  Asthma control during long term treatment with regular inhaled salbutamol and salmeterol , 1998, Thorax.

[52]  M. Sears,et al.  Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.

[53]  J. Benovic,et al.  Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle. , 1998, American journal of respiratory cell and molecular biology.

[54]  S. Elsayed,et al.  Effects of β2 adrenoceptor agonists on T‐cell subpopulations , 1998 .

[55]  I. Adcock,et al.  Transcription factors and asthma. , 1998, The European respiratory journal.

[56]  Proud,et al.  Intranasal salmeterol inhibits allergen‐induced vascular permeability but not mast cell activation or cellular infiltration , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[57]  S. Oddera,et al.  Salmeterol Enhances the Inhibitory Activity of Dexamethasone on Allergen-Induced Blood Mononuclear Cell Activation , 1998, Respiration.

[58]  L. Boulet,et al.  Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. , 1998, The European respiratory journal.

[59]  B. Lipworth,et al.  Effects of treatment with formoterol on bronchoprotection against methacholine. , 1998, The American journal of medicine.

[60]  T L Petty,et al.  Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. , 1998, The Journal of allergy and clinical immunology.

[61]  E. Naline,et al.  Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. , 1998, The European respiratory journal.

[62]  I. Hall,et al.  Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. , 1998, The Journal of allergy and clinical immunology.

[63]  B. J. Knoll,et al.  Salmeterol‐induced desensitization, internalization and phosphorylation of the human β2‐adrenoceptor , 1998, British journal of pharmacology.

[64]  B. Davies,et al.  The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. , 1998, Respiratory medicine.

[65]  F. Simons,et al.  A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. , 1997, The New England journal of medicine.

[66]  M. W. Jensen,et al.  Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. , 1997, American journal of respiratory and critical care medicine.

[67]  R. Sakalauskas,et al.  Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. , 1997, The European respiratory journal.

[68]  Bissonnette Ey,et al.  Anti-inflammatory effect of β2-agonists: Inhibition of TNF-α release from human mast cells , 1997 .

[69]  K. Chung,et al.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. , 1997, The New England journal of medicine.

[70]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[71]  Robert J. Lefkowitz,et al.  Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.

[72]  J. Lötvall,et al.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[73]  Brian Lipworth,et al.  Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics , 1997, The Lancet.

[74]  D. Postma,et al.  Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. , 1997, Thorax.

[75]  Lesley Rushton,et al.  Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study , 1997, BMJ.

[76]  S. Wenzel,et al.  The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. , 1997, Chest.

[77]  M. Teixeira,et al.  Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo. , 1997, European journal of pharmacology.

[78]  P. Henricks,et al.  Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. , 1997, The American journal of physiology.

[79]  T. Troost,et al.  Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. , 1997, American journal of respiratory and critical care medicine.

[80]  P. Barnes,et al.  Effect of short- and long-acting β2-adrenoceptor agonists on pulmonary β2-adrenoceptor expression in human lung , 1996 .

[81]  D. Yates,et al.  An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. , 1996, American journal of respiratory and critical care medicine.

[82]  J. Walters,et al.  Salmeterol tachyphylaxis in steroid treated asthmatic subjects. , 1996, Thorax.

[83]  K. Chung,et al.  Mechanisms of impaired beta-adrenoceptor-induced airway relaxation by interleukin-1beta in vivo in the rat. , 1996, The Journal of clinical investigation.

[84]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[85]  T. Hunter,et al.  A growing coactivator network , 1996, Nature.

[86]  R Barber,et al.  Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution. , 1996, Molecular pharmacology.

[87]  J. V. van Noord,et al.  Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. , 1996, The European respiratory journal.

[88]  P. Leblanc,et al.  A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. , 1996, American journal of respiratory and critical care medicine.

[89]  H. Bisgaard,et al.  Duration of action of formoterol and salbutamol dry‐powder inhalation in prevention of exercise‐induced asthma in children , 1996 .

[90]  J. Douglas,et al.  Functional and binding characteristics of long-acting beta 2-agonists in lung and heart. , 1996, American journal of respiratory and critical care medicine.

[91]  D. Romberger,et al.  Beta-adrenergic agonists attenuate fibroblast-mediated contraction of released collagen gels. , 1996, The American journal of physiology.

[92]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[93]  D. Griffith,et al.  Differential effects of salmeterol on lung endothelial and epithelial leakage in sheep. , 1996, Journal of applied physiology.

[94]  R. Wilson,et al.  Anti‐inflammatory, membrane‐stabilizing interactions of salmeterol with human neutrophils in vitro , 1996, British journal of pharmacology.

[95]  F. Hargreave,et al.  Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. , 1996, The European respiratory journal.

[96]  B. Lipworth,et al.  Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. , 1996, Thorax.

[97]  D. Postma,et al.  Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. , 1995, American journal of respiratory and critical care medicine.

[98]  R. Challiss,et al.  Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle , 1995, British journal of pharmacology.

[99]  G. Russell,et al.  Salmeterol xinafoate in children on high dose inhaled steroids. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[100]  P. Mansueto,et al.  Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[101]  D. Yates,et al.  Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. , 1995, American journal of respiratory and critical care medicine.

[102]  P. Barnes,et al.  Beta-adrenergic receptors and their regulation. , 1995, American journal of respiratory and critical care medicine.

[103]  S. O'Donnell,et al.  The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo , 1995, British journal of pharmacology.

[104]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[105]  W. Lenney,et al.  Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. , 1995, Respiratory medicine.

[106]  R. Davies,et al.  Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. , 1995, American journal of respiratory and critical care medicine.

[107]  K. Rabe,et al.  Paradoxical blockade of beta adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. , 1995, The Journal of pharmacology and experimental therapeutics.

[108]  I. Adcock,et al.  Beta-adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung. , 1995, European journal of pharmacology.

[109]  B. Champion,et al.  Anti‐inflammatory activity of salmeterol: down‐regulation of cytokine production , 1995, Clinical and experimental immunology.

[110]  P. Black,et al.  Effects of glucocorticoids and beta-adrenoceptor agonists on the proliferation of airway smooth muscle. , 1995, European journal of pharmacology.

[111]  M. Teixeira,et al.  Anti-inflammatory effects of a short-acting and a long-acting β2-adrenoceptor agonist in guinea pig skin , 1995 .

[112]  J. Kemp,et al.  Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. , 1994, American journal of respiratory and critical care medicine.

[113]  M. Johnson,et al.  Inhibitory actions of salmeterol on human airway macrophages and blood monocytes. , 1994, European journal of pharmacology.

[114]  C. Bolliger,et al.  Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. , 1994, The European respiratory journal.

[115]  B. Waldeck,et al.  The interaction between salmeterol and β2‐adrenoceptor agonists with higher efficacy on guinea‐pig trachea and human bronchus in vitro , 1994, British journal of pharmacology.

[116]  D. Hendrick,et al.  Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. , 1994, American journal of respiratory and critical care medicine.

[117]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[118]  B. Lipworth,et al.  Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. , 1994, The American journal of medicine.

[119]  D. McDonald,et al.  Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol. , 1994, Journal of applied physiology.

[120]  C. Ulrik,et al.  Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. , 1994, The European respiratory journal.

[121]  B. Lipworth,et al.  Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. , 1994, Respiratory medicine.

[122]  E. Naline,et al.  Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. , 1994, The European respiratory journal.

[123]  A. Boner,et al.  Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. , 1994, American journal of respiratory and critical care medicine.

[124]  D. McDonald,et al.  The beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. , 1994, The American journal of physiology.

[125]  K. Rabe,et al.  Why are long-acting beta-adrenoceptor agonists long-acting? , 1994, The European respiratory journal.

[126]  M. Johnson,et al.  Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. , 1994, European journal of pharmacology.

[127]  S. Raspanti,et al.  Salmeterol inhibits anaphylactic histamine release from guinea‐pig isolated mast cells , 1994, The Journal of pharmacy and pharmacology.

[128]  M. Lohse,et al.  Molecular mechanisms of membrane receptor desensitization. , 1993, Biochimica et biophysica acta.

[129]  M. Johnson,et al.  Comparison of the anti‐inflammatory properties of formoterol, salbutamol and salmeterol in guinea‐pig skin and lung , 1993, British journal of pharmacology.

[130]  Jerry R. Meyer,et al.  Enhancement of intersubband Stark effects in L‐valley step quantum wells for infrared modulation and voltage tunable detection , 1993 .

[131]  R. Dahl,et al.  The effect of salmeterol on the early‐ and late‐phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X , 1993, Allergy.

[132]  H. Magnussen,et al.  Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. , 1993, The American review of respiratory disease.

[133]  S. Liggett,et al.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.

[134]  G. Verleden,et al.  Beta 2-adrenoceptor agonists inhibit NANC neural bronchoconstrictor responses in vitro. , 1993, Journal of applied physiology.

[135]  K. Rabe,et al.  Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. , 1993, European journal of pharmacology.

[136]  C. Print,et al.  Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. , 1993, Thorax.

[137]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[138]  P. O'Byrne,et al.  Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. , 1992, The American review of respiratory disease.

[139]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[140]  M. Linden,et al.  The effects of β2‐adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes , 1992, British journal of pharmacology.

[141]  M. Hughes,et al.  Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. , 1992, The American review of respiratory disease.

[142]  T. Haahtela,et al.  A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. , 1992, The Journal of allergy and clinical immunology.

[143]  S. Pedersen,et al.  Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. , 1992, The Journal of allergy and clinical immunology.

[144]  E. Naline,et al.  Formoterol and salbutamol inhibit bradykinin‐ and histamine‐induced airway microvascular leakage in guinea‐pig , 1992, British journal of pharmacology.

[145]  R. Pauwels,et al.  The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. , 1992, The Journal of allergy and clinical immunology.

[146]  P. Jeffery,et al.  Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. , 1992, The American review of respiratory disease.

[147]  M. Johnson,et al.  Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea‐pig lung and skin , 1992, British journal of pharmacology.

[148]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[149]  N. Choudry,et al.  A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. , 1992, The Journal of allergy and clinical immunology.

[150]  R. Pauwels,et al.  Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. , 1992, Thorax.

[151]  P. Leff,et al.  Estimation of the efficacy and affinity of the β2‐adrenoceptor agonist salmeterol in guinea‐pig trachea , 1991, British journal of pharmacology.

[152]  M. Johnson,et al.  Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lung , 1991, British journal of pharmacology.

[153]  C. Persson,et al.  Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. , 1991, The American review of respiratory disease.

[154]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[155]  P. O'Byrne,et al.  Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. , 1991, The American review of respiratory disease.

[156]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[157]  C. Löfdahl,et al.  Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. , 1989, Allergy.

[158]  A. Ullman,et al.  Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. , 1988, Thorax.

[159]  R. Hancox,et al.  Asthma exacerbations during long term (cid:226) agonist use: influence of (cid:226) 2 adrenoceptor polymorphism , 2000 .

[160]  D. Postma,et al.  Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts. , 2000, The European respiratory journal.

[161]  V. Backer,et al.  Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. , 1999, Canadian respiratory journal.

[162]  P. Howarth,et al.  The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. , 1999, American journal of respiratory and critical care medicine.

[163]  C. Ezeamuzie,et al.  Differential effects of salbutamol and salmeterol on human eosinophil responses. , 1998, The Journal of pharmacology and experimental therapeutics.

[164]  B. Lipworth,et al.  Concomitant administration of low-dose prednisolone protects against in vivo beta2-adrenoceptor subsensitivity induced by regular formoterol. , 1998, Chest.

[165]  E. Duiverman,et al.  Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. , 1998, American journal of respiratory and critical care medicine.

[166]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[167]  R. Roorda,et al.  One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. , 1997, American journal of respiratory and critical care medicine.

[168]  I. Adcock,et al.  Interactions of glucocorticoids and beta 2-agonists. , 1996, The European respiratory journal.

[169]  P. Barnes,et al.  Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. , 1995, The American journal of physiology.

[170]  R. Townley,et al.  Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation. , 1993, International archives of allergy and immunology.

[171]  R. Lefkowitz,et al.  Regulation of β-Adrenergic Receptors by Steroid Hormones , 1984 .